Investigation of oxacillinases type beta-lactamases in carbapenems resistant Acinetobacter baumannii clinical isolates

Q3 Medicine
H. Özçelik, Tuba Yıldırım, S. Marakli, Ö. İdil
{"title":"Investigation of oxacillinases type beta-lactamases in carbapenems resistant Acinetobacter baumannii clinical isolates","authors":"H. Özçelik, Tuba Yıldırım, S. Marakli, Ö. İdil","doi":"10.1097/MRM.0000000000000226","DOIUrl":null,"url":null,"abstract":"Acinetobacter baumannii, one of the most important infectious agents spread in hospitals, is an opportunistic, Gram-negative, aerobic and nonfermentative pathogen causing outbreaks often in ICUs and difficulties in treatments due to multiple antibiotic resistance characteristics. Carbapenem resistance in A. baumannii is a growing public health concern and most often mediated by oxacillinases carbapenemases. Carbapenems are significant representatives of the group β-lactamases that are used in the treatment of A. baumannii. OXA-23, OXA-24, OXA-51 and OXA-58 are the most common type of OXA gene family members which are responsible for carbapenem resistance. This study aimed to identify the carbapenem resistant A. baumannii isolates in ICU and analyse OXA-23, OXA-24, OXA-51 and OXA-58 genes’ expressions by using reverse transcritptase-PCR. In this study, A. baumannii isolates collected from the respiratory tract samples obtained from the patients receiving treatment between June 2017 and January 2018 at the ICU in Amasya University Sabuncuoğlu Serefeddin Education and Research Hospital. Collected samples identified by VITEK-2 device. Resistance profiles of carbapenem-resistant strains against to cefepime, ceftazidime, ciprofloxacin, levofloxacin, amikacin, gentamicin, tetracycline, tigecycline and colistin antibiotics were determined by disk diffusion and minimum inhibition concentration tests. Moreover, OXA-23, OXA-24, OXA-51 and OXA-58 genes were investigated by reverse transcritptase-PCR. Identified 50 A. baumannii isolates were found to be 100% resistant to imipenem, meropenem, cefepime, ceftazidime and ciprofloxacin, 94% for levofloxacin, 68% for amikacin, 78% for gentamicin, 88% for tetracycline and 6% for tigecycline. It was detected that all samples are susceptible to colistin and showed multiple antibiotic resistance. As a result of molecular analyses, it was also determined that the expressions of only OXA-23 and OXA-51 genes in all isolates. This study is one of the first reports to analyse A. baumannii isolated from respiratory tract samples in terms of microbiological and molecular analyses.","PeriodicalId":49625,"journal":{"name":"Reviews in Medical Microbiology","volume":"36 1","pages":"209 - 214"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Medical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MRM.0000000000000226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Acinetobacter baumannii, one of the most important infectious agents spread in hospitals, is an opportunistic, Gram-negative, aerobic and nonfermentative pathogen causing outbreaks often in ICUs and difficulties in treatments due to multiple antibiotic resistance characteristics. Carbapenem resistance in A. baumannii is a growing public health concern and most often mediated by oxacillinases carbapenemases. Carbapenems are significant representatives of the group β-lactamases that are used in the treatment of A. baumannii. OXA-23, OXA-24, OXA-51 and OXA-58 are the most common type of OXA gene family members which are responsible for carbapenem resistance. This study aimed to identify the carbapenem resistant A. baumannii isolates in ICU and analyse OXA-23, OXA-24, OXA-51 and OXA-58 genes’ expressions by using reverse transcritptase-PCR. In this study, A. baumannii isolates collected from the respiratory tract samples obtained from the patients receiving treatment between June 2017 and January 2018 at the ICU in Amasya University Sabuncuoğlu Serefeddin Education and Research Hospital. Collected samples identified by VITEK-2 device. Resistance profiles of carbapenem-resistant strains against to cefepime, ceftazidime, ciprofloxacin, levofloxacin, amikacin, gentamicin, tetracycline, tigecycline and colistin antibiotics were determined by disk diffusion and minimum inhibition concentration tests. Moreover, OXA-23, OXA-24, OXA-51 and OXA-58 genes were investigated by reverse transcritptase-PCR. Identified 50 A. baumannii isolates were found to be 100% resistant to imipenem, meropenem, cefepime, ceftazidime and ciprofloxacin, 94% for levofloxacin, 68% for amikacin, 78% for gentamicin, 88% for tetracycline and 6% for tigecycline. It was detected that all samples are susceptible to colistin and showed multiple antibiotic resistance. As a result of molecular analyses, it was also determined that the expressions of only OXA-23 and OXA-51 genes in all isolates. This study is one of the first reports to analyse A. baumannii isolated from respiratory tract samples in terms of microbiological and molecular analyses.
耐碳青霉烯类鲍曼不动杆菌临床分离株中oxacillinases型β -内酰胺酶的研究
鲍曼不动杆菌是一种机会性、革兰氏阴性、需氧、非发酵病原菌,是医院传播最重要的感染性病原体之一,常在重症监护病房暴发,且由于多种抗生素耐药特点,治疗困难。鲍曼不动杆菌对碳青霉烯类药物的耐药性是一个日益严重的公共卫生问题,最常由氧杆菌酶介导。碳青霉烯类是用于治疗鲍曼不动杆菌的β-内酰胺酶的重要代表。OXA-23、OXA-24、OXA-51和OXA-58是引起碳青霉烯类耐药的OXA基因家族成员中最常见的类型。本研究旨在鉴定ICU中耐碳青霉烯类鲍曼不动杆菌分离株,并采用逆转录酶- pcr方法分析OXA-23、OXA-24、OXA-51和OXA-58基因的表达。在本研究中,从2017年6月至2018年1月在Amasya大学Sabuncuoğlu Serefeddin教育与研究医院ICU接受治疗的患者的呼吸道样本中收集鲍曼不稳定杆菌分离株。采集的样品经VITEK-2装置鉴定。采用纸片扩散法和最小抑制浓度法测定碳青霉烯耐药菌株对头孢吡肟、头孢他啶、环丙沙星、左氧氟沙星、阿米卡星、庆大霉素、四环素、替加环素和粘菌素等抗生素的耐药性。利用逆转录酶- pcr对OXA-23、OXA-24、OXA-51和OXA-58基因进行检测。50株鲍曼不动杆菌对亚胺培南、美罗培南、头孢吡肟、头孢他啶和环丙沙星耐药100%,对左氧氟沙星耐药94%,对阿米卡星耐药68%,对庆大霉素耐药78%,对四环素耐药88%,对替加环素耐药6%。所有样品均对粘菌素敏感,并表现出多种抗生素耐药。分子分析结果还表明,所有分离株中仅表达OXA-23和OXA-51基因。本研究是首次报道从呼吸道样本中分离出鲍曼不动杆菌的微生物学和分子分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reviews in Medical Microbiology
Reviews in Medical Microbiology 生物-微生物学
CiteScore
1.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Reviews in Medical Microbiology is a quarterly review journal which provides a balanced coverage of the whole field of medical microbiology. The Journal publishes state-of-the art reviews, mini-reviews, case presentations and original research from on-going research of the latest developments and techniques in medical microbiology, virology, mycology, parasitology, clinical microbiology, and hospital infection.​ In addition, PhD-Review - a platform for young researchers, and biographical Bio-Sketch articles are also considered. Reviews are concise, authoritative, and readable synthesis of the latest information on its subject, and references are limited to the fifty key sources for full reviews and twenty for mini-reviews. Reviews in Medical Microbiology is the perfect way for both qualified and trainee microbiologists, and researchers and clinicians with an interest in microbiology, to stay fully informed of the latest developments in medical microbiology. The journal is a valuable resource for educational and teaching purposes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信